Abstract
Background
Panniculitis, or inflammation of adipose tissue, includes a heterogeneous group of disorders with similar morphologic presentations. Currently, panniculitides are classified based on histopathologic findings only.
Objective
In this retrospective study of 207 cases of biopsy-proven panniculitis over 20 years at Mayo Clinic, we aimed to propose a new classification that integrates the clinical morphologic features with the histopathology of panniculitis.
Methods
We collected patient demographic and lesion morphologic characteristics using lesion photographs and physician notes for each of our 207 cases, including location, ulceration, scale, pattern (unilateral versus circumferential), atrophy/sclerosis (cicatricial), redness, and swelling.
Results
The panniculitides most likely to ulcerate were calciphylaxis (85.7% ulcerating), pancreatic panniculitis (66.6%), and α1-antitrypsin deficiency-associated panniculitis (100%). The panniculitides least likely to ulcerate were erythema nodosum and medication-induced and granulomatous panniculitis. This retrospective study used only descriptions in clinical notes and available medical photographs.
Conclusion
We present an updated classification schema of panniculitides based on clinical findings. The primary distinctions are based on ulceration, location, and number of lesions. Although complete distinction of all panniculitides based on clinical examination alone is not possible, we hope the proposed schema allows clinicians to tailor differential diagnoses.
References
Shavit E, Marzano AV, Alavi A. Ulcerative versus non-ulcerative panniculitis: is it time for a novel clinical approach to panniculitis? Int J Dermatol. 2021;60(4):407–17.
Velter C, Lipsker D. Cutaneous panniculitis [in French]. Rev Med Interne. 2016;37(11):743–50.
Durosaro O, Davis MD, Reed KB, Rohlinger AL. Incidence of cutaneous lupus erythematosus, 1965–2005: a population-based study. Arch Dermatol. 2009;145(3):249–53.
Blake T, Manahan M, Rodins K. Erythema nodosum: a review of an uncommon panniculitis. Dermatol Online J. 2014;20(4):22376.
Wick MR. Panniculitis: a summary. Semin Diagn Pathol. 2017;34(3):261–72.
Borroni G, Giorgini C, Tomasini C, Brazzelli V. How to make a specific diagnosis of panniculitis on clinical grounds alone: an integrated pathway of general criteria and specific findings. G Ital Dermatol Venereol. 2013;148(4):325–33.
Requena L. Normal subcutaneous fat, necrosis of adipocytes and classification of the panniculitides. Semin Cutan Med Surg. 2007;26(2):66–70.
Requena L. Panniculitis. Philadelphia: Saunders; 2008.
Morrison LK, Rapini R, Willison CB, Tyring S. Infection and panniculitis. Dermatol Ther. 2010;23(4):328–40.
Leung AKC, Leong KF, Lam JM. Erythema nodosum. World J Pediatr. 2018;14(6):548–54.
Filotico R, Mastrandrea V. Cutaneous lupus erythematosus: clinico-pathologic correlation. G Ital Dermatol Venereol. 2018;153(2):216–29.
Fraga J, Garcia-Diez A. Lupus erythematosus panniculitis. Dermatol Clin. 2008;26(4):453–63.
Hansen CB, Callen JP. Connective tissue panniculitis: lupus panniculitis, dermatomyositis, morphea/scleroderma. Dermatol Ther. 2010;23(4):341–9.
Herrerin CL, et al. El lupus paniculitis: una paniculitis mixta. 1987.
Martens PB, Moder KG, Ahmed I. Lupus panniculitis: clinical perspectives from a case series. J Rheumatol. 1999;26(1):68–72.
Requena L, Sanchez Yus E. Panniculitis. Part II. Mostly lobular panniculitis. J Am Acad Dermatol. 2001;45(3):325–61.
Bonkemeyer Millan S, Gan R, Townsend PE. Venous ulcers: diagnosis and treatment. Am Fam Physician. 2019;100(5):298–305.
Alavi A, Sibbald RG, Phillips TJ, Miller OF, Margolis DJ, Marston W, et al. What’s new: management of venous leg ulcers: approach to venous leg ulcers. J Am Acad Dermatol. 2016;74(4):627–40.
Miteva M, Romanelli P, Kirsner RS. Lipodermatosclerosis. Dermatol Ther. 2010;23(4):375–88.
Chan MP. Neutrophilic panniculitis: algorithmic approach to a heterogeneous group of disorders. Arch Pathol Lab Med. 2014;138(10):1337–43.
Llamas-Velasco M, Fraga J, Sanchez-Schmidt JM, Fernandez-Figueras M, Gallardo F, Rutten A, et al. Neutrophilic infiltrates in panniculitis: comprehensive review and diagnostic algorithm proposal. Am J Dermatopathol. 2020;42(10):717–30.
Takeshita M, Imayama S, Oshiro Y, Kurihara K, Okamoto S, Matsuki Y, et al. Clinicopathologic analysis of 22 cases of subcutaneous panniculitis-like CD56- or CD56+ lymphoma and review of 44 other reported cases. Am J Clin Pathol. 2004;121(3):408–16.
Baxi KD, Rathod SP, Chaudhary RG, Jagati A. Subcutaneous panniculitis-like T-cell lymphoma. Indian J Dermatol Venereol Leprol. 2020;86(5):606.
Willemze R, Jansen PM, Cerroni L, Berti E, Santucci M, Assaf C, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood. 2008;111(2):838–45.
Mazhar AR, Johnson RJ, Gillen D, Stivelman JC, Ryan MJ, Davis CL, et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int. 2001;60(1):324–32.
Choy B, Chou S, Anforth R, Fernandez-Penas P. Panniculitis in patients treated with BRAF inhibitors: a case series. Am J Dermatopathol. 2014;36(6):493–7.
Vazquez-Osorio I, Sanchez-Aguilar MD, Garcia-Rodino S, Suarez-Penaranda JM, Aliste C, Vazquez-Veiga H. Vemurafenib-induced neutrophilic panniculitis: a new case and review of the literature. Am J Dermatopathol. 2016;38(7):e93–6.
Finelt N, Lulla RR, Melin-Aldana H, Ruth JS, Lin FY, Su JM, et al. Bumps in the road: panniculitis in children and adolescents treated with vemurafenib. Pediatr Dermatol. 2017;34(3):337–41.
Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: part II: inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol. 2015;72(2):221–36.
Piroth M, Frenard C, Eugene-Lamer J, Dreno B, Quereux G. Panniculitis during BRAF inhibitor and/or MEK inhibitor therapy: a new case report and literature review [in French]. Ann Dermatol Venereol. 2020;147(12):833–41.
Kismet E, Demirkaya E, Koseoglu V, Deveci S, Atay AA. Panniculitis induced by a chemotherapy regimen consisting of topotecan and cyclophosphamide. Pediatr Blood Cancer. 2005;44(1):98–9.
Mohamednour A, Khan S, Sunmboye K, Kinder A. A rare case of anti-TNF induced panniculitis. Rheumatol Adv Pract. 2020;2020:4.
Lambert JLW, De Schepper S, Speeckaert R. Cutaneous manifestations in biological-treated inflammatory bowel disease patients: a narrative review. J Clin Med. 2021;10(5):1040.
Mavrikakis I, Georgiadis T, Fragiadaki K, Sfikakis PP. Orbital lobular panniculitis in Weber-Christian disease: sustained response to anti-TNF treatment and review of the literature. Surv Ophthalmol. 2010;55(6):584–9.
Antwi-Amoabeng D, Ghuman J, Ghuman J, Beutler BD, Ulanja MB, Kuriakose K, et al. Ponatinib-associated panniculitis: case report and review of the literature. Cancer Treat Res Commun. 2021;27: 100357.
Sibaud V, Beylot-Barry M, Protin C, Vigarios E, Recher C, Ysebaert L. Dermatological toxicities of Bruton’s tyrosine kinase inhibitors. Am J Clin Dermatol. 2020;21(6):799–812.
Borroni G, Torti S, D’Ospina RM, Pezzini C. Drug-induced panniculitides. G Ital Dermatol Venereol. 2014;149(2):263–70.
Fabbro SK, Smith SM, Dubovsky JA, Gru AA, Jones JA. Panniculitis in patients undergoing treatment with the Bruton tyrosine kinase inhibitor ibrutinib for lymphoid leukemias. JAMA Oncol. 2015;1(5):684–6.
Stewart J, Bayers S, Vandergriff T. Self-limiting ibrutinib-induced neutrophilic panniculitis. Am J Dermatopathol. 2018;40(2):e28–9.
Acknowledgments
Marianne Mallia, ELS, MWC, Senior Scientific/Medical Editor, Mayo Clinic, substantively edited the manuscript. The Scientific Publications staff at Mayo Clinic provided proofreading, administrative, and clerical support.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
Nimay Anand is funded by the Vanderbilt Medical Scholars Program. No other funding sources were used to assist in the preparation of this article.
Conflicts of interest
Afsaneh Alavi is an investigator for Boehringer Ingelheim and Processa Pharmaceuticals, and a consultant for AbbVie, Boehringer Ingelheim, InflaRx, Novartis, and UCB. Nimay C. Anand, Mika Takaichi, Emma F. Johnson, David A. Wetter, and Mark D.P. Davis have no conflicts of interest to declare.
Availability of data and material
All data generated and/or analyzed during this study are included in this published article (and its supplementary information files).
Code availability
Not applicable.
Ethics approval
This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Mayo Clinic Institutional Review Board (#20-010125).
Consent to participate
The Mayo Clinic Institutional Review Board approved the study and waived written informed consent for those who provided research authorization.
Consent for publication
Not applicable.
Author contributions
Concept and design: EFJ, DAW, AA. Acquisition, analysis, or interpretation of data: NCA, EFJ, AA. Drafting of the manuscript: NCA, AA. Critical revision of the manuscript: All authors.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Anand, N.C., Takaichi, M., Johnson, E.F. et al. Suggestions for a New Clinical Classification Approach to Panniculitis Based on a Mayo Clinic Experience of 207 Cases. Am J Clin Dermatol 23, 739–746 (2022). https://doi.org/10.1007/s40257-022-00709-9
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40257-022-00709-9